Jodi Cook Net Worth

Jodi Cook biography

Jodi A. Cook serves as Independent Director of the Company. Previously she was one of the founding members and Chief Operating Officer of Agilis Biotherapeutics, a clinical-stage company focused on gene therapies for rare diseases of the central nervous system, from December 2013 until its acquisition by PTC Therapeutics in August 2018. While at Agilis she led the sale of the company to PTC in a deal that represented significant value to all parties. Dr. Cook’s career spans a wide range of experiences including VP of Clinical Research at InSound Medical and Director of Audiology at Songbird Hearing, both successful biotech start-up companies within the hearing industry. She has been Assistant Professor of Audiology and Director of the Hearing Aid Program at Mayo Clinic. Dr Cook earned a BA from Loyola University in Maryland, M.Aud. from University of South Carolina, and PhD from Arizona State University in Hearing Science. She completed a clinical fellowship at Johns Hopkins School of Medicine in Baltimore, MD. Her extensive scientific, clinical and executive business experience depends the Boards collective qualifications, skills and expertise.

What is the salary of Jodi Cook?

As the Independent Director of Fennec Pharmaceuticals Inc, the total compensation of Jodi Cook at Fennec Pharmaceuticals Inc is $112,434. There are 10 executives at Fennec Pharmaceuticals Inc getting paid more, with Rostislav Raykov having the highest compensation of $1,477,140.

Insiders trading at Fennec Pharmaceuticals Inc

Over the last 10 years, insiders at Fennec Pharmaceuticals Inc have traded over $13,607,192 worth of Fennec Pharmaceuticals Inc stock and bought 1,966,488 units worth $9,890,813 . The most active insiders traders include Management Pr, Llcmancheste..., Spacavazza Paolo Cavazza En... a Rosty Raykov. On average, Fennec Pharmaceuticals Inc executives and independent directors trade stock every 69 days with the average trade being worth of $442,734. The most recent stock trade was executed by Rosty Raykov on 31 August 2024, trading 2,431 units of FENC stock currently worth $13,419.

What does Fennec Pharmaceuticals Inc do?

fennec pharmaceuticals inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the united states. its lead product pedmark, a formulation of sodium thiosulfate, which has completed the phase iii clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. the company was formerly known as adherex technologies inc. and changed its name to fennec pharmaceuticals inc. in september 2014. fennec pharmaceuticals inc. was founded in 1996 and is based in research triangle park, north carolina.

Fennec Pharmaceuticals Inc executives and stock owners

Fennec Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Rostislav Raykov,
  Chief Executive Officer, Director
• Shubh Goel,
  Chief Commercial Officer
• Robert Andrade,
  Chief Financial Officer
• Rostislav Raykov,
  CEO & Director
• Shubh Goel,
  Chief Commercial Officer
• Robert C. Andrade,
  Chief Financial Officer
• Khalid Islam,
  Independent Chairman of the Board
• Chris Rallis,
  Independent Director
• Adrian Haigh,
  Independent Director
• Marco Brughera,
  Independent Director
• Jodi Cook,
  Independent Director
• Alexander D. Smith M.S.,
  Consultant
• Anne McKay,
  Regulatory Consultant
• Lei Fang,
  Pres of Pharstat Inc
• Mark Gowland,
  Controller
• Management Pr, Llcmancheste...,
  
• Management Co Llc Mancheste...,
  
• Spacavazza Paolo Cavazza En...,
  
• Capital Advisors Lp Southpo...,
  
• Jeffrey S. Hackman,
  Chief Executive Officer
• Rosty Raykov,